Physician profile
Eric Haralson
NPI 1871961797
$4,849.75
in general payments reported to CMS, 2019-2025
44 companies · $1,033 in 2025
The $1,033 reported for 2025 was more than what 81% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $882 · 2022: $1,087 · 2023: $1,077 · 2024: $772 · 2025: $1,033.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,881.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,881.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $736.04 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $463.57 | 2021-2025 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $344.53 | 2022-2025 | Rybelsus, Ozempic, Wegovy |
| Abbott Laboratories | $337.03 | 2021-2025 | Freestyle Libre 3 |
| Amgen INC. | $281.31 | 2021-2025 | Otezla, Repatha, Repatha |
| Bayer Healthcare Pharmaceuticals INC. | $269.85 | 2022-2025 | |
| Dexcom, INC. | $256.78 | 2021-2025 | Dexcom G6 Transmitter |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $255.99 | 2024-2025 | Caplyta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $207.30 | 2021-2025 | Jardiance |
| Pfizer INC. | $147.46 | 2022-2025 | |
| Gilead Sciences, INC. | $127.18 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $115.67 | 2022-2023 | Januvia, Belsomra, Steglatro |
| Astellas Pharma US INC | $110.31 | 2022-2024 | Veozah, Myrbetriq |
| Glaxosmithkline, LLC. | $105.82 | 2022-2024 | Arexvy, Shingrix, Trelegy Ellipta |
| Idorsia Pharmaceuticals US INC | $93.12 | 2023-2024 | Quviviq |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Haralson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.